Teva reports first quarter 2023 financial results and reaffirms 2023 non-gaap outlook

Tel aviv, israel--(business wire)--teva pharmaceutical industries ltd. (nyse and tase: teva) today reported results for the quarter ended march 31, 2023. revenues of $3.7 billion gaap loss per share of $0.18 non-gaap diluted eps of $0.40 cash flow used in operating activities of $145 million free cash flow of $41 million non-gaap gross profit margin of 49.1% was mainly impacted by an unfavorable portfolio mix and an increase in cogs due to inflationary pressure. we expect our gross profit margi.
TEVA Ratings Summary
TEVA Quant Ranking